Related Experiment Video
Updated: Jul 13, 2026

08:29
Symmetric Bihemispheric Postmortem Brain Cutting to Study Healthy and Pathological Brain Conditions in Humans
Published on: December 18, 2016
Quantifying metabolic asymmetry modulo structure in Alzheimer's disease
P Thomas Fletcher1, Stephanie Powell, Norman L Foster
1School of Computing, University of Utah, Salt Lake City, UT, USA.
Summary
We developed a novel method to measure brain metabolic asymmetry, accounting for structural differences. This technique aids in studying Alzheimer's disease (AD) by providing precise comparisons between brain hemispheres.
Area of Science:
- Neuroimaging
- Medical Image Analysis
- Computational Anatomy
Background:
- Metabolic asymmetry in the brain is a potential biomarker for neurological disorders like Alzheimer's disease (AD).
- Quantifying metabolic asymmetry is challenging due to confounding structural hemispheric differences.
- Existing methods may not adequately disentangle metabolic changes from anatomical variations.
Purpose of the Study:
- To introduce a new computational framework for quantifying metabolic asymmetry in the brain, independent of structural variations.
- To establish a method for comparing metabolic differences between brain hemispheres in individuals and populations.
- To apply this methodology to neuroimaging data from Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort.
Main Methods:
- Utilizing large deformation diffeomorphic metric mapping (LDDMM) for anatomical atlas construction.
- Defining a structurally symmetric coordinate frame based on LDDMM invariance properties.
- Mapping individual metabolic asymmetry to a common population-wide symmetric coordinate system.
Main Results:
- Demonstrated the feasibility of creating subject-specific structurally symmetric coordinate systems.
- Successfully quantified metabolic asymmetry modulo structural differences in AD patients.
- Established a statistical framework for population-level analysis of metabolic asymmetry using LDDMM.
Conclusions:
- The proposed LDDMM-based method effectively quantifies metabolic asymmetry while controlling for structural variations.
- This approach offers a robust tool for investigating brain alterations in Alzheimer's disease and other neurological conditions.
- The framework facilitates population-level statistical analysis of brain asymmetry in neuroimaging studies.
Related Concept Videos
Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
